Orforglipron vs Enclomiphene
Side-by-side comparison of key properties, dosing, and research.
GLP-1 / Weight Loss Agonists
OrforglipronGLP-1 / Weight Loss Agonists
Enclomiphene- Summary
- Orforglipron is an oral, once-daily small-molecule GLP-1 receptor agonist developed by Eli Lilly. Unlike injectable GLP-1 peptides, it is a non-peptide compound absorbed orally without food restrictions, representing a major convenience advancement. Phase 2 trials showed up to 9.4% weight loss at 36 weeks, and Phase 3 trials (ATTAIN program) are ongoing for obesity and type 2 diabetes.
- Enclomiphene is the trans-isomer of clomiphene citrate, a selective estrogen receptor modulator (SERM) that stimulates endogenous testosterone production by blocking estrogen negative feedback on the hypothalamus and pituitary. Unlike TRT, it restores testosterone while preserving or increasing sperm production and testicular volume.
- Half-Life
- ~12 hours (once-daily oral dosing)
- 5-7 days (long half-life; accumulates)
- Admin Route
- Oral
- Oral
- Research
- —
- —
- Typical Dose
- 12 mg → 24 mg → 36 mg → 45 mg
- 12.5-25 mg per day
- Frequency
- Once daily
- Once daily or every other day
- Key Benefits
- Oral pill — no injections required
- Once-daily dosing without food restrictions (unlike oral semaglutide)
- Up to 9.4% body weight reduction in Phase 2 at 36 weeks
- Significant HbA1c reduction in type 2 diabetes trials
- Small-molecule stability — no cold chain requirements
- Broadens access for injection-averse patients
- Potential class-defining convenience advantage over injectable GLP-1s
- Restores testosterone to normal range without exogenous androgen administration
- Preserves or increases sperm production and fertility
- Maintains testicular volume (unlike TRT which causes testicular atrophy)
- LH and FSH levels rise, indicating intact HPG axis function
- Option for hypogonadal men desiring fertility
- Oral administration (no injection required)
- Side Effects
- Nausea (most common, dose-dependent)
- Vomiting
- Diarrhea
- Decreased appetite
- +2 more
- Visual disturbances (rare but class-related SERM effect)
- Mood changes or irritability
- Hot flashes
- Elevated estradiol in some users
- +2 more
- Stacks With
- —
- —